{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:11:14Z","timestamp":1791612674919,"version":"4.3.4"},"reference-count":270,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Plan Nacional de I+D+I"},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Subdirecci\u00f3n General de Redes y Centros de Investigaci\u00f3n Cooperativa"},{"name":"Spanish Ministry of Economy and Competitiveness"},{"name":"Spanish Network for Research in Infectious Diseases"},{"name":"European Development Regional Fund (EDRF)"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.cmi.2018.02.002","type":"journal-article","created":{"date-parts":[[2018,2,12]],"date-time":"2018-02-12T12:49:44Z","timestamp":1518439784000},"page":"S21-S40","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":228,"special_numbering":"S2","title":["ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors)"],"prefix":"10.1016","volume":"24","author":[{"given":"K.L.","family":"Winthrop","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Mariette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.T.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Benamu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.H.","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Dumusc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.S.","family":"Smolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Aguado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Fern\u00e1ndez-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2018.02.002_bib1","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.cmi.2018.01.029","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (introduction)","volume":"24","author":"Fern\u00e1ndez-Ruiz","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2018.02.002_bib2","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/BOR.0000000000000361","article-title":"The novel interleukin-1 cytokine family members in inflammatory diseases","volume":"29","author":"Hahn","year":"2017","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.cmi.2018.02.002_bib3","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/BOR.0000000000000266","article-title":"Anti-inflammatory panacea? The expanding therapeutics of interleukin-1 blockade","volume":"28","author":"Kahlenberg","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.cmi.2018.02.002_bib4","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2217\/imt.14.106","article-title":"The inflammasome and IL-1\u03b2: implications for the treatment of inflammatory diseases","volume":"7","author":"Satoh","year":"2015","journal-title":"Immunotherapy"},{"key":"10.1016\/j.cmi.2018.02.002_bib5","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3389\/fphar.2016.00380","article-title":"A\u00a0Snapshot on the on-label and off-label use of the interleukin-1 inhibitors in Italy among rheumatologists and pediatric rheumatologists: a nationwide multi-center retrospective observational study","volume":"7","author":"Vitale","year":"2016","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cmi.2018.02.002_bib6","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jbspin.2012.07.018","article-title":"Efficacy of anakinra in calcium pyrophosphate crystal-induced arthritis: a report of 16 cases and review of the literature","volume":"80","author":"Ottaviani","year":"2013","journal-title":"Joint, Bone, Spine Rev Rhumatisme"},{"key":"10.1016\/j.cmi.2018.02.002_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.autrev.2014.08.008","article-title":"Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Beh\u00e7et's disease","volume":"14","author":"Cantarini","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.cmi.2018.02.002_bib8","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.amjcard.2015.07.047","article-title":"Effectiveness and safety of anakinra for management of refractory pericarditis","volume":"116","author":"Jain","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cmi.2018.02.002_bib9","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s40257-017-0265-1","article-title":"PAPA, PASH and PAPASH syndromes: pathophysiology, presentation and treatment","volume":"18","author":"Cugno","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.cmi.2018.02.002_bib10","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.002_bib11","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.smim.2013.10.008","article-title":"Treating inflammation by blocking interleukin-1 in humans","volume":"25","author":"Dinarello","year":"2013","journal-title":"Semin Immunol"},{"key":"10.1016\/j.cmi.2018.02.002_bib12","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1097-2765(02)00599-3","article-title":"The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-\u03b2","volume":"10","author":"Martinon","year":"2002","journal-title":"Mol Cell"},{"key":"10.1016\/j.cmi.2018.02.002_bib13","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/imr.12534","article-title":"Molecular mechanisms and functions of pyroptosis, inflammatory caspases and inflammasomes in infectious diseases","volume":"277","author":"Man","year":"2017","journal-title":"Immunol Rev"},{"key":"10.1016\/j.cmi.2018.02.002_bib14","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1126\/science.282.5396.2085","article-title":"Defective LPS signaling in C3H\/HeJ and C57BL\/10ScCr mice: mutations in Tlr4 gene","volume":"282","author":"Poltorak","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.cmi.2018.02.002_bib15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.tim.2014.09.007","article-title":"Response of host inflammasomes to viral infection","volume":"23","author":"Chen","year":"2015","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.cmi.2018.02.002_bib16","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1099\/jgv.0.000401","article-title":"Beyond the inflammasome: regulatory NOD-like receptor modulation of the host immune response following virus exposure","volume":"97","author":"Coutermarsh-Ott","year":"2016","journal-title":"J\u00a0Gen Virol"},{"key":"10.1016\/j.cmi.2018.02.002_bib17","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.vaccine.2010.10.045","article-title":"Blocking IL-1\u03b1 but not IL-1\u03b2 increases susceptibility to chronic Mycobacterium tuberculosis infection in mice","volume":"29","author":"Guler","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2018.02.002_bib18","doi-asserted-by":"crossref","first-page":"179174","DOI":"10.1155\/2013\/179174","article-title":"Pattern recognition receptors and cytokines in Mycobacterium tuberculosis infection\u2013the double-edged sword?","volume":"2013","author":"Hossain","year":"2013","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.cmi.2018.02.002_bib19","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1054\/tuld.1998.0009","article-title":"Assessment of the interleukin 1 gene cluster and other candidate gene polymorphisms in host susceptibility to tuberculosis","volume":"79","author":"Bellamy","year":"1998","journal-title":"Tubercle Lung Dis"},{"key":"10.1016\/j.cmi.2018.02.002_bib20","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1471-2350-11-37","article-title":"Polymorphisms in IL-1\u03b2, vitamin D receptor Fok1, and Toll-like receptor 2 are associated with extrapulmonary tuberculosis","volume":"11","author":"Motsinger-Reif","year":"2010","journal-title":"BMC Med Genet"},{"key":"10.1016\/j.cmi.2018.02.002_bib21","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1093\/infdis\/jiu636","article-title":"IL1B and DEFB1 polymorphisms increase susceptibility to invasive mold infection after solid-organ transplantation","volume":"211","author":"Wojtowicz","year":"2015","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2018.02.002_bib22","doi-asserted-by":"crossref","first-page":"R25","DOI":"10.1186\/ar4159","article-title":"Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator","volume":"15","author":"Terkeltaub","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.cmi.2018.02.002_bib23","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1002\/art.27600","article-title":"Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study","volume":"62","author":"So","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cmi.2018.02.002_bib24","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1186\/ar2143","article-title":"A\u00a0pilot study of IL-1 inhibition by anakinra in acute gout","volume":"9","author":"So","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.cmi.2018.02.002_bib25","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1002\/art.10578","article-title":"Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial","volume":"46","author":"Nuki","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cmi.2018.02.002_bib26","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/art.10870","article-title":"Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial","volume":"48","author":"Fleischmann","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cmi.2018.02.002_bib27","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1136\/ard.2005.048371","article-title":"Safety of extended treatment with anakinra in patients with rheumatoid arthritis","volume":"65","author":"Fleischmann","year":"2006","journal-title":"Ann Rheumatic Dis"},{"key":"10.1016\/j.cmi.2018.02.002_bib28","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/art.10141","article-title":"Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial","volume":"46","author":"Cohen","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cmi.2018.02.002_bib29","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/art.20221","article-title":"Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate","volume":"50","author":"Genovese","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cmi.2018.02.002_bib30","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/ard.2004.033662","article-title":"Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice","volume":"65","author":"den Broeder","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2018.02.002_bib31","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/RHU.0b013e31812e00a1","article-title":"Reactivation of pulmonary tuberculosis in a patient with rheumatoid arthritis during treatment with IL-1 receptor antagonists (anakinra)","volume":"13","author":"Settas","year":"2007","journal-title":"J\u00a0Clin Rheumatol"},{"key":"10.1016\/j.cmi.2018.02.002_bib32","first-page":"734","article-title":"Tuberculous pyomyositis in a rheumatoid arthritis patient treated with anakinra","volume":"33","author":"Migkos","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.cmi.2018.02.002_bib33","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1136\/annrheumdis-2011-200908","article-title":"Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions","volume":"71","author":"Schlesinger","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2018.02.002_bib34","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1136\/ard.2010.144063","article-title":"Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study","volume":"70","author":"Schlesinger","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2018.02.002_bib35","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.3899\/jrheum.131226","article-title":"Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study","volume":"41","author":"Sundy","year":"2014","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.cmi.2018.02.002_bib36","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa0810787","article-title":"Use of canakinumab in the cryopyrin-associated periodic syndrome","volume":"360","author":"Lachmann","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.002_bib37","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJMoa055137","article-title":"Neonatal-onset multisystem inflammatory disease responsive to interleukin-1\u03b2 inhibition","volume":"355","author":"Goldbach-Mansky","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.002_bib38","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/art.25057","article-title":"Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease\/chronic infantile neurologic, cutaneous, articular syndrome","volume":"62","author":"Neven","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cmi.2018.02.002_bib39","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/art.30149","article-title":"Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle\u2013Wells syndrome","volume":"63","author":"Kuemmerle-Deschner","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cmi.2018.02.002_bib40","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1002\/art.34409","article-title":"Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes","volume":"64","author":"Sibley","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cmi.2018.02.002_bib41","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1093\/rheumatology\/kew208","article-title":"Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes","volume":"55","author":"Kullenberg","year":"2016","journal-title":"Rheumatology (Oxf)"},{"key":"10.1016\/j.cmi.2018.02.002_bib42","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/jama.2016.15826","article-title":"Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence: the AIRTRIP Randomized Clinical Trial","volume":"316","author":"Brucato","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2018.02.002_bib43","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.clinthera.2012.09.009","article-title":"Long-term efficacy and safety profile of rilonacept in the treatment of cryopyrin-associated periodic syndromes: results of a 72-week open-label extension study","volume":"34","author":"Hoffman","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.cmi.2018.02.002_bib44","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3109\/03009742.2014.992949","article-title":"Efficacy and safety of biological agents in adult-onset Still's disease","volume":"44","author":"Cavalli","year":"2015","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.cmi.2018.02.002_bib45","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/acr.21989","article-title":"Treatment of acute gouty arthritis in complex hospitalized patients with anakinra","volume":"65","author":"Ghosh","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.cmi.2018.02.002_bib46","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","article-title":"Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis","volume":"367","author":"Ruperto","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.002_bib47","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/ard.2007.076034","article-title":"Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France","volume":"67","author":"Lequerr\u00e9","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2018.02.002_bib48","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13075-017-1222-3","article-title":"Treatment of mucocutaneous manifestations in Beh\u00e7et's disease with anakinra: a pilot open-label study","volume":"19","author":"Grayson","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.cmi.2018.02.002_bib49","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s10067-015-3004-0","article-title":"Efficacy and safety profile of anti-interleukin-1 treatment in Beh\u8efbt's disease: a multicenter retrospective study","volume":"35","author":"Emmi","year":"2016","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.cmi.2018.02.002_bib50","first-page":"353","article-title":"Anakinra long-term efficacy and safety in the management of Schnitzler's syndrome and latent tuberculosis infection","volume":"34","author":"Lopalco","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.cmi.2018.02.002_bib51","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/ijd.13337","article-title":"Long-term efficacy and safety of anakinra in a patient with Beh\u00e7et's disease and concomitant tuberculosis infection","volume":"56","author":"Emmi","year":"2017","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.cmi.2018.02.002_bib52","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10067-009-1279-8","article-title":"Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Beh\u00e7et's disease","volume":"29","author":"Bilginer","year":"2010","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.cmi.2018.02.002_bib53","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1128\/CVI.00175-10","article-title":"Influenza and meningococcal vaccinations are effective in healthy subjects treated with the interleukin-1 \u03b2-blocking antibody canakinumab: results of an open-label, parallel group, randomized, single-center study","volume":"17","author":"Chioato","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.cmi.2018.02.002_bib54","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1093\/cid\/cit684","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"66","key":"10.1016\/j.cmi.2018.02.002_bib55","doi-asserted-by":"crossref","first-page":"136","DOI":"10.15585\/mmwr.mm6605e2","article-title":"Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older \u2013 United States","volume":"2017","author":"Kim","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.cmi.2018.02.002_bib56","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/ACI.0000000000000251","article-title":"Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs","volume":"16","author":"Varricchi","year":"2016","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.cmi.2018.02.002_bib57","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/pro.2072","article-title":"Structural basis of interleukin-5 dimer recognition by its \u03b1 receptor","volume":"21","author":"Kusano","year":"2012","journal-title":"Protein Sci"},{"key":"10.1016\/j.cmi.2018.02.002_bib58","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/JAA.S40244","article-title":"Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases","volume":"8","author":"Menzella","year":"2015","journal-title":"J\u00a0Asthma Allergy"},{"key":"10.1016\/j.cmi.2018.02.002_bib59","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.jaci.2008.02.033","article-title":"Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex\u00a0vivo and increases IL-5 and IL-5 receptor levels","volume":"121","author":"Stein","year":"2008","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.cmi.2018.02.002_bib60","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1080\/17476348.2016.1176532","article-title":"Mepolizumab for the reduction of exacerbations in severe eosinophilic asthma","volume":"10","author":"Russell","year":"2016","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.cmi.2018.02.002_bib61","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.002_bib62","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa1708208","article-title":"Mepolizumab for eosinophilic chronic obstructive pulmonary disease","volume":"377","author":"Pavord","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.002_bib63","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.jaip.2017.01.013","article-title":"Combination omalizumab and mepolizumab therapy for refractory allergic bronchopulmonary aspergillosis","volume":"5","author":"Altman","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.cmi.2018.02.002_bib64","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa070812","article-title":"Treatment of patients with the hypereosinophilic syndrome with mepolizumab","volume":"358","author":"Rothenberg","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.002_bib65","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jaci.2012.07.055","article-title":"Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes","volume":"131","author":"Roufosse","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.cmi.2018.02.002_bib66","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1398-9995.2005.00791.x","article-title":"Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis","volume":"60","author":"Oldhoff","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.cmi.2018.02.002_bib67","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jaci.2017.05.044","article-title":"Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial","volume":"140","author":"Bachert","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.cmi.2018.02.002_bib68","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2011.07.044","article-title":"An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis","volume":"141","author":"Assa'ad","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cmi.2018.02.002_bib69","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1177\/1753465817717134","article-title":"Reslizumab in the treatment of inadequately controlled asthma in adults and adolescents with elevated blood eosinophils: clinical trial evidence and future prospects","volume":"11","author":"Maspero","year":"2017","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.cmi.2018.02.002_bib70","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.iac.2007.07.008","article-title":"Evaluation and differential diagnosis of marked, persistent eosinophilia","volume":"27","author":"Nutman","year":"2007","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.cmi.2018.02.002_bib71","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.0105-2896.2004.00192.x","article-title":"Interleukin-4- and interleukin-13-mediated host protection against intestinal nematode parasites","volume":"201","author":"Finkelman","year":"2004","journal-title":"Immunol Rev"},{"key":"10.1016\/j.cmi.2018.02.002_bib72","doi-asserted-by":"crossref","first-page":"746","DOI":"10.4269\/ajtmh.16-0348","article-title":"Human helminths and allergic disease: the hygiene hypothesis and beyond","volume":"95","author":"Santiago","year":"2016","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.cmi.2018.02.002_bib73","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and exacerbations of refractory eosinophilic asthma","volume":"360","author":"Haldar","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.002_bib74","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.002_bib75","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.002_bib76","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.alit.2016.11.006","article-title":"Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma","volume":"66","author":"Shimoda","year":"2017","journal-title":"Allergol Int"},{"key":"10.1016\/j.cmi.2018.02.002_bib77","doi-asserted-by":"crossref","first-page":"e59872","DOI":"10.1371\/journal.pone.0059872","article-title":"Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2018.02.002_bib78","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/j.clinthera.2016.07.010","article-title":"Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study","volume":"38","author":"Lugogo","year":"2016","journal-title":"Clin Ther"},{"key":"10.1016\/j.cmi.2018.02.002_bib79","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.rmed.2016.12.009","article-title":"Comparative effectiveness of mepolizumab and omalizumab in severe asthma: an indirect treatment comparison","volume":"123","author":"Cockle","year":"2017","journal-title":"Respir Med"},{"key":"10.1016\/j.cmi.2018.02.002_bib80","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cmi.2018.02.002_bib81","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.chest.2016.03.018","article-title":"Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts","volume":"150","author":"Corren","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.cmi.2018.02.002_bib82","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.chest.2016.03.032","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study","volume":"150","author":"Bjermer","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.cmi.2018.02.002_bib83","article-title":"Efficacy and safety of anti-interleukin-5 therapy in patients with asthma: a systematic review and meta-analysis","volume":"11","author":"Wang","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2018.02.002_bib84","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1586\/17476348.2015.1000867","article-title":"Efficacy and safety of reslizumab in patients with moderate to severe eosinophilic asthma","volume":"9","author":"Lim","year":"2015","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.cmi.2018.02.002_bib85","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nrrheum.2014.127","article-title":"IL-6 biology: implications for clinical targeting in rheumatic disease","volume":"10","author":"Calabrese","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.cmi.2018.02.002_bib86","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.002_bib87","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S1470-2045(14)70319-5","article-title":"Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial","volume":"15","author":"van Rhee","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cmi.2018.02.002_bib88","doi-asserted-by":"crossref","first-page":"R141","DOI":"10.1186\/ar3455","article-title":"Integrated safety in tocilizumab clinical trials","volume":"13","author":"Schiff","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.cmi.2018.02.002_bib89","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrrheum.2017.83","article-title":"The role of IL-6 in host defense against infections: immunobiology and clinical implications","volume":"13","author":"Rose-John","year":"2017","journal-title":"Nature Rev Rheumatol"},{"key":"10.1016\/j.cmi.2018.02.002_bib90","first-page":"81","article-title":"Tocilizumab: a review of its safety and efficacy in rheumatoid arthritis","volume":"3","author":"Jones","year":"2010","journal-title":"Clin Med Insights: Arthritis Musculoskeletal Disorders"},{"key":"10.1016\/j.cmi.2018.02.002_bib91","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/BOR.0000000000000255","article-title":"The biology behind interleukin-6 targeted interventions","volume":"28","author":"Liu","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.cmi.2018.02.002_bib92","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ni.3153","article-title":"IL-6 as a keystone cytokine in health and disease","volume":"16","author":"Hunter","year":"2015","journal-title":"Nat Immunol"},{"key":"10.1016\/j.cmi.2018.02.002_bib93","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s10875-015-0187-8","article-title":"The ying and yang of STAT3 in human disease","volume":"35","author":"Vogel","year":"2015","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.cmi.2018.02.002_bib94","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/annrheumdis-2016-210310","article-title":"Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial","volume":"76","author":"Burmester","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2018.02.002_bib95","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1136\/annrheumdis-2013-204760","article-title":"Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study","volume":"73","author":"Genovese","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2018.02.002_bib96","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/art.39093","article-title":"Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study","volume":"67","author":"Genovese","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.cmi.2018.02.002_bib97","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/art.39700","article-title":"The efficacy and safety of clazakizumab, an anti-interleukin-6 monoclonal antibody, in a phase IIb study of adults with active psoriatic arthritis","volume":"68","author":"Mease","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.cmi.2018.02.002_bib98","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1136\/annrheumdis-2013-205137","article-title":"Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2018.02.002_bib99","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3109\/14397595.2015.1074648","article-title":"Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: results from a randomized phase II trial","volume":"26","author":"Takeuchi","year":"2016","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.cmi.2018.02.002_bib100","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1002\/art.39249","volume":"67","author":"Weinblatt","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.cmi.2018.02.002_bib101","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1136\/annrheumdis-2011-201087","article-title":"Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and\/or TNF inhibitors: a large, open-label study close to clinical practice","volume":"71","author":"Bykerk","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2018.02.002_bib102","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s13075-015-0880-2","article-title":"Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials","volume":"17","author":"Strand","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.cmi.2018.02.002_bib103","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/rheumatology\/kev372","article-title":"ROUTINE-a prospective, multicentre, non-interventional, observational study to evaluate the safety and effectiveness of intravenous tocilizumab for the treatment of active rheumatoid arthritis in daily practice in Germany","volume":"55","author":"Iking-Konert","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cmi.2018.02.002_bib104","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/14397595.2016.1206507","article-title":"Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: the FIRST Bio study","volume":"27","author":"Ishiguro","year":"2017","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.cmi.2018.02.002_bib105","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3899\/jrheum.130466","article-title":"Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan","volume":"41","author":"Koike","year":"2014","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.cmi.2018.02.002_bib106","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/annrheumdis-2013-204011","article-title":"Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy","volume":"74","author":"Yun","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2018.02.002_bib107","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1002\/art.39761","article-title":"Risk for gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologics","volume":"68","author":"Xie","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.cmi.2018.02.002_bib108","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/acr.22470","article-title":"Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy","volume":"67","author":"Yun","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.cmi.2018.02.002_bib109","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1007\/s00296-011-2060-2","article-title":"Unchanged serum viral load and liver function during tocilizumab treatment in a patient with rheumatoid arthritis and hepatitis C virus infection","volume":"32","author":"Nagashima","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.cmi.2018.02.002_bib110","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1093\/rheumatology\/ken384","article-title":"Long-term tocilizumab therapy in a patient with rheumatoid arthritis and chronic hepatitis B","volume":"47","author":"Nagashima","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cmi.2018.02.002_bib111","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3109\/s10165-011-0470-3","article-title":"A\u00a0patient with rheumatoid arthritis treated with tocilizumab together with lamivudine prophylaxis after remission of infliximab-reactivated hepatitis B","volume":"21","author":"Tsuboi","year":"2011","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.cmi.2018.02.002_bib112","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/1756-185X.12359","article-title":"Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs","volume":"19","author":"Nakamura","year":"2016","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.cmi.2018.02.002_bib113","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.rdc.2016.09.012","article-title":"Hepatitis B reactivation in rheumatic diseases: screening and prevention","volume":"43","author":"Koutsianas","year":"2017","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.cmi.2018.02.002_bib114","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/hep.27716","article-title":"Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection","volume":"62","author":"Barone","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.cmi.2018.02.002_bib115","unstructured":"US Food and Drug Administration. \u201cStelara\u201d (ustekinumab). Revised: 09\/2016. Washington DC: FDA."},{"key":"10.1016\/j.cmi.2018.02.002_bib116","series-title":"\u201cStelara\u201d (ustekinumab). Summary of product characteristics","author":"European Medicines Agency","year":"2016"},{"key":"10.1016\/j.cmi.2018.02.002_bib117","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1365-2133.2010.09855.x","article-title":"Treatment of pityriasis rubra pilaris with ustekinumab","volume":"163","author":"Wohlrab","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.cmi.2018.02.002_bib118","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1684\/ejd.2016.2854","article-title":"Interstitial granulomatous dermatitis occurring in a patient with SAPHO syndrome one month after starting leflunomide, and subsequently disappearing with ustekinumab","volume":"26","author":"Cornillier","year":"2016","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.cmi.2018.02.002_bib119","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1001\/archdermatol.2012.78","article-title":"Ustekinumab for pyoderma gangrenosum","volume":"148","author":"Kluger","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.cmi.2018.02.002_bib120","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/bjd.14338","article-title":"Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum","volume":"174","author":"Blok","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.cmi.2018.02.002_bib121","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.0105-2896.2004.00214.x","article-title":"IL-12 and IL-23: master regulators of innate and adaptive immunity","volume":"202","author":"Langrish","year":"2004","journal-title":"Immunol Rev"},{"key":"10.1016\/j.cmi.2018.02.002_bib122","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S1471-4906(01)02060-9","article-title":"The biology of human natural killer-cell subsets","volume":"22","author":"Cooper","year":"2001","journal-title":"Trends Immunol"},{"key":"10.1016\/j.cmi.2018.02.002_bib123","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1365-2567.2008.03027.x","article-title":"CD56bright natural killer (NK) cells: an important NK cell subset","volume":"126","author":"Poli","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.cmi.2018.02.002_bib124","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S1074-7613(03)00296-6","article-title":"The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses","volume":"19","author":"Trinchieri","year":"2003","journal-title":"Immunity"},{"key":"10.1016\/j.cmi.2018.02.002_bib125","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.smim.2014.09.008","article-title":"Mendelian susceptibility to mycobacterial disease: genetic, immunological, and clinical features of inborn errors of IFN-\u03b3 immunity","volume":"26","author":"Bustamante","year":"2014","journal-title":"Semin Immunol"},{"key":"10.1016\/j.cmi.2018.02.002_bib126","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/MD.0b013e3181fdd832","article-title":"Revisiting human IL-12R\u03b21 deficiency: a survey of 141 patients from 30 countries","volume":"89","author":"de Beaucoudrey","year":"2010","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.cmi.2018.02.002_bib127","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1074\/jbc.M207577200","article-title":"Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17","volume":"278","author":"Aggarwal","year":"2003","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.cmi.2018.02.002_bib128","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/ACI.0b013e328358cc0b","article-title":"Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis","volume":"12","author":"Puel","year":"2012","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.cmi.2018.02.002_bib129","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/bjd.15015","article-title":"Candida infections in psoriasis and psoriatic arthritis patients treated with IL-17 inhibitors and their practical management","volume":"177","author":"Saunte","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.cmi.2018.02.002_bib130","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2018.02.002_bib131","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.002_bib132","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jdermsci.2011.05.005","article-title":"Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)","volume":"63","author":"Tsai","year":"2011","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.cmi.2018.02.002_bib133","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jaad.2015.07.002","article-title":"Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study","volume":"73","author":"Landells","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.cmi.2018.02.002_bib134","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.002_bib135","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaad.2016.08.008","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.cmi.2018.02.002_bib136","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2018.02.002_bib137","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2018.02.002_bib138","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn's disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.002_bib139","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jaad.2011.06.041","article-title":"Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials","volume":"66","author":"Gordon","year":"2012","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.cmi.2018.02.002_bib140","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamadermatol.2015.0718","article-title":"Risk of serious infection with biologic and systemic treatment of psoriasis: results from the psoriasis longitudinal assessment and registry (PSOLAR)","volume":"151","author":"Kalb","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.cmi.2018.02.002_bib141","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/1346-8138.12370","article-title":"Risk of herpes zoster in psoriatic patients undergoing biologic treatment","volume":"41","author":"Umezawa","year":"2014","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.cmi.2018.02.002_bib142","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/jdv.12307","article-title":"The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions","volume":"28","author":"Adelzadeh","year":"2014","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.cmi.2018.02.002_bib143","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000323736","article-title":"Ustekinumab and herpes zoster","volume":"222","author":"Failla","year":"2011","journal-title":"Dermatology"},{"key":"10.1016\/j.cmi.2018.02.002_bib144","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/1346-8138.13755","article-title":"Varicella zoster virus meningitis under ustekinumab because of plaque psoriasis","volume":"44","author":"Stollberger","year":"2017","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.cmi.2018.02.002_bib145","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/bjd.12461","article-title":"The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C","volume":"169","author":"Chiu","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.cmi.2018.02.002_bib146","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ad.2015.01.010","article-title":"Risk of reactivation of hepatitis b virus infection in psoriasis patients treated with biologics: a retrospective analysis of 20 cases from the BIOBADADERM database","volume":"106","author":"Sanz-Bueno","year":"2015","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.cmi.2018.02.002_bib147","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1517\/14712598.2016.1121986","article-title":"Secukinumab for treating plaque psoriasis","volume":"16","author":"Rothstein","year":"2016","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.cmi.2018.02.002_bib148","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.coi.2011.07.006","article-title":"Recent advances in the IL-17 cytokine family","volume":"23","author":"Gaffen","year":"2011","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.cmi.2018.02.002_bib149","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.1365-2133.2012.11099.x","article-title":"Psoriasis: rationale for targeting interleukin-17","volume":"167","author":"Girolomoni","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.cmi.2018.02.002_bib150","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrrheum.2015.53","article-title":"The IL-23\u2013IL-17 axis in inflammatory arthritis","volume":"11","author":"Lubberts","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.cmi.2018.02.002_bib151","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.cmi.2018.02.002_bib152","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.bpg.2014.04.005","article-title":"Not all monoclonals are created equal - lessons from failed drug trials in Crohn's disease","volume":"28","author":"Kaser","year":"2014","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.cmi.2018.02.002_bib153","unstructured":"Novartis annouces FDA approval for first IL-17A antagonist Cosentyx (TM) (secukinumab) for moderate-to-severe plaque psoriasis (Media Release) 2015 (last accession: 30 June 2017). Available at: https:\/\/www.novartis.com\/news\/media-releases\/novartis-announces-fda-approval-first-il-17a-antagonist-cosentyxtm-secukinumab."},{"key":"10.1016\/j.cmi.2018.02.002_bib154","series-title":"Novartis receives two new FDA approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis in the US [Media Release]","year":"2016"},{"key":"10.1016\/j.cmi.2018.02.002_bib155","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2147\/CCID.S111007","article-title":"Emerging targeted therapies for plaque psoriasis \u2013 impact of ixekizumab","volume":"10","author":"Kazemi","year":"2017","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.cmi.2018.02.002_bib156","series-title":"FDA approves new psoriasis drug Taltz (Media Release)","year":"2016"},{"key":"10.1016\/j.cmi.2018.02.002_bib157","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1080\/1744666X.2016.1246957","article-title":"Brodalumab for the treatment of psoriasis","volume":"12","author":"Galluzzo","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.cmi.2018.02.002_bib158","series-title":"FDA approves new psoriasis drug (Media Release)","year":"2017"},{"key":"10.1016\/j.cmi.2018.02.002_bib159","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1080\/14740338.2016.1221923","article-title":"Safety of secukinumab in the treatment of psoriasis","volume":"15","author":"Blauvelt","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.cmi.2018.02.002_bib160","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1038\/jid.2015.144","article-title":"IL-23\/IL-17A dysfunction phenotypes inform possible clinical effects from anti-IL-17A therapies","volume":"135","author":"Blauvelt","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.cmi.2018.02.002_bib161","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0001-7310(14)70016-X","article-title":"IL-17 and infections","volume":"105","author":"Ling","year":"2014","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.cmi.2018.02.002_bib162","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1038\/cti.2017.34","article-title":"Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections","volume":"6","author":"Kammuller","year":"2017","journal-title":"Clin Transl Immunol"},{"key":"10.1016\/j.cmi.2018.02.002_bib163","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2016.03.024","article-title":"Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis","volume":"75","author":"van de Kerkhof","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.cmi.2018.02.002_bib164","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.002_bib165","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","article-title":"Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial","volume":"382","author":"Baeten","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2018.02.002_bib166","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s13555-016-0121-x","article-title":"Brodalumab for the treatment of psoriasis: a review of phase III trials","volume":"6","author":"Farahnik","year":"2016","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.cmi.2018.02.002_bib167","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40261-017-0500-9","article-title":"Safety and efficacy of brodalumab for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis","volume":"37","author":"Attia","year":"2017","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.cmi.2018.02.002_bib168","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1111\/bjd.15723","article-title":"Infections from 7 clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis","volume":"177","author":"Papp","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.cmi.2018.02.002_bib169","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/bjd.15015","article-title":"Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management","volume":"177","author":"Saunte","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.cmi.2018.02.002_bib170","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.4049\/jimmunol.158.3.1438","article-title":"Down-regulation of Fc\u03b5RI expression on human basophils during in\u00a0vivo treatment of atopic patients with anti-IgE antibody","volume":"158","author":"MacGlashan","year":"1997","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.cmi.2018.02.002_bib171","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.rmed.2010.07.011","article-title":"Omalizumab-induced decrease of FcxiRI expression in patients with severe allergic asthma","volume":"104","author":"Chanez","year":"2010","journal-title":"Respir Med"},{"key":"10.1016\/j.cmi.2018.02.002_bib172","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.2147\/DDDT.S112208","article-title":"A\u00a0review of omalizumab for the management of severe asthma","volume":"10","author":"Lin","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.cmi.2018.02.002_bib173","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1586\/1744666X.2015.993971","article-title":"Omalizumab for the treatment of chronic urticaria","volume":"11","author":"Zuberbier","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.cmi.2018.02.002_bib174","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1136\/thoraxjnl-2013-203738","article-title":"Against all odds: anti-IgE for intrinsic asthma?","volume":"69","author":"Lommatzsch","year":"2014","journal-title":"Thorax"},{"key":"10.1016\/j.cmi.2018.02.002_bib175","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.jaci.2016.05.038","article-title":"Efficacy of omalizumab in patients with atopic dermatitis: a systematic review and meta-analysis","volume":"138","author":"Wang","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.cmi.2018.02.002_bib176","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jmii.2013.10.003","article-title":"Anti-IgE therapy for allergic bronchopulmonary aspergillosis","volume":"49","author":"Homma","year":"2016","journal-title":"J\u00a0Microbiol Immunol Infect"},{"key":"10.1016\/j.cmi.2018.02.002_bib177","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jaip.2014.12.008","article-title":"Clinical efficacy and immunologic effects of omalizumab in allergic bronchopulmonary aspergillosis","volume":"3","author":"Voskamp","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.cmi.2018.02.002_bib178","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s12016-015-8490-y","article-title":"Off-label uses of omalizumab","volume":"50","author":"El-Qutob","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.cmi.2018.02.002_bib179","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1398-9995.2007.01601.x","article-title":"Geohelminth infections: a review of the role of IgE and assessment of potential risks of anti-IgE treatment","volume":"63","author":"Cooper","year":"2008","journal-title":"Allergy"},{"key":"10.1016\/j.cmi.2018.02.002_bib180","first-page":"178","article-title":"Production and activities of IgE in helminth infection","volume":"31","author":"Jarrett","year":"1982","journal-title":"Prog Allergy"},{"key":"10.1016\/j.cmi.2018.02.002_bib181","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nri2199","article-title":"Protective immune mechanisms in helminth infection","volume":"7","author":"Anthony","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.cmi.2018.02.002_bib182","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jaci.2006.02.028","article-title":"Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma","volume":"117","author":"Noga","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.cmi.2018.02.002_bib183","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.cmi.2018.02.002_bib184","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1183\/09031936.02.00278102","article-title":"Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma","volume":"20","author":"Buhl","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cmi.2018.02.002_bib185","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S1081-1206(10)62170-9","article-title":"Omalizumab is effective in the long-term control of severe allergic asthma","volume":"91","author":"Lanier","year":"2003","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.cmi.2018.02.002_bib186","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1398-9995.2004.00533.x","article-title":"Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma","volume":"59","author":"Ayres","year":"2004","journal-title":"Allergy"},{"key":"10.1016\/j.cmi.2018.02.002_bib187","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1398-9995.2004.00550.x","article-title":"Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR","volume":"59","author":"Vignola","year":"2004","journal-title":"Allergy"},{"key":"10.1016\/j.cmi.2018.02.002_bib188","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","article-title":"Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE","volume":"60","author":"Humbert","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.cmi.2018.02.002_bib189","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1009705","article-title":"Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children","volume":"364","author":"Busse","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.002_bib190","article-title":"Similar efficacy with omalizumab in chronic idiopathic\/spontaneous urticaria despite different background therapy","volume":"3","author":"Casale","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.cmi.2018.02.002_bib191","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1001\/jama.286.23.2956","article-title":"Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial","volume":"286","author":"Casale","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2018.02.002_bib192","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1067\/mai.2002.121949","article-title":"Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis","volume":"109","author":"Kuehr","year":"2002","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.cmi.2018.02.002_bib193","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S1081-1206(10)62171-0","article-title":"Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis","volume":"91","author":"Chervinsky","year":"2003","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.cmi.2018.02.002_bib194","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2013.05.013","article-title":"Omalizumab in patients with symptomatic chronic idiopathic\/spontaneous urticaria despite standard combination therapy","volume":"132","author":"Kaplan","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.cmi.2018.02.002_bib195","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jaci.2014.02.007","article-title":"Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab","volume":"134","author":"Long","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.cmi.2018.02.002_bib196","series-title":"\u201cXolair\u201d (omalizumab). Summary of product characteristics","year":"2015"},{"key":"10.1016\/j.cmi.2018.02.002_bib197","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jaci.2007.06.015","article-title":"Anti-IgE treatment of eosinophil-associated gastrointestinal disorders","volume":"120","author":"Foroughi","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.cmi.2018.02.002_bib198","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2222.2007.02650.x","article-title":"Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection","volume":"37","author":"Cruz","year":"2007","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.cmi.2018.02.002_bib199","doi-asserted-by":"crossref","first-page":"71","DOI":"10.7754\/Clin.Lab.2012.120406","article-title":"Clinical course and side effects of anti-IgE monoclonal antibody in patients with severe persistent asthma","volume":"59","author":"Yalcin","year":"2013","journal-title":"Clin Lab"},{"key":"10.1016\/j.cmi.2018.02.002_bib200","first-page":"199","article-title":"Echinococcus multilocularis infection in a patient treated with omalizumab","volume":"23","author":"Skiepko","year":"2013","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"10.1016\/j.cmi.2018.02.002_bib201","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.acc.2016.06.001","article-title":"Overview of laboratory testing and clinical presentations of complement deficiencies and dysregulation","volume":"77","author":"Frazer-Abel","year":"2016","journal-title":"Adv Clin Chem"},{"key":"10.1016\/j.cmi.2018.02.002_bib202","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1749-6632.2009.04633.x","article-title":"Clinical significance of complement deficiencies","volume":"1173","author":"Pettigrew","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.cmi.2018.02.002_bib203","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.clim.2015.08.009","article-title":"Applying complement therapeutics to rare diseases","volume":"161","author":"Reis","year":"2015","journal-title":"Clin Immunol"},{"key":"10.1016\/j.cmi.2018.02.002_bib204","unstructured":"Food and Drug Administration. Eculizumab Available at: http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/UCM217725.pdf."},{"key":"10.1016\/j.cmi.2018.02.002_bib205","unstructured":"European Medicines Agency. Soliris: EPAR Product Information Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000791\/WC500054208.pdf."},{"key":"10.1016\/j.cmi.2018.02.002_bib206","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/ejh.12543","article-title":"Pathophysiology, diagnosis, and treatment of paroxysmal nocturnal hemoglobinuria: a review","volume":"95","author":"Devalet","year":"2015","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.cmi.2018.02.002_bib207","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3324\/haematol.2009.016121","article-title":"Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab","volume":"95","author":"Helley","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.cmi.2018.02.002_bib208","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.thromres.2012.04.001","article-title":"Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation","volume":"130","author":"Weitz","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.cmi.2018.02.002_bib209","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1182\/blood-2007-06-095646","article-title":"Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria","volume":"110","author":"Hillmen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2018.02.002_bib210","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood-2007-06-094136","article-title":"Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria","volume":"111","author":"Brodsky","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2018.02.002_bib211","doi-asserted-by":"crossref","first-page":"6786","DOI":"10.1182\/blood-2011-02-333997","article-title":"Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival","volume":"117","author":"Kelly","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2018.02.002_bib212","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrneph.2012.214","article-title":"French Study Group for a HCG. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies","volume":"8","author":"Zuber","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.cmi.2018.02.002_bib213","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.2014.423","article-title":"Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies","volume":"87","author":"Licht","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.cmi.2018.02.002_bib214","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1111\/j.1600-6143.2012.04252.x","article-title":"Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation","volume":"12","author":"Zuber","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cmi.2018.02.002_bib215","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1097\/TP.0000000000000200","article-title":"Atypical hemolytic uremic syndrome recurrence after kidney transplantation","volume":"98","author":"Matar","year":"2014","journal-title":"Transplantation"},{"key":"10.1016\/j.cmi.2018.02.002_bib216","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/MOT.0000000000000249","article-title":"Eculizumab use in kidney transplantation","volume":"20","author":"Johnson","year":"2015","journal-title":"Curr Opin Organ Transplant"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.cmi.2018.02.002_bib217","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/nep.12935","article-title":"Suspected atypical haemolytic uraemic syndrome in two post-partum patients with foetal-death in utero responding to eculizumab","volume":"22","author":"Chua","year":"2017","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.cmi.2018.02.002_bib218","doi-asserted-by":"crossref","first-page":"e6056","DOI":"10.1097\/MD.0000000000006056","article-title":"Complement-mediated thrombotic microangiopathy secondary to sepsis-induced disseminated intravascular coagulation successfully treated with eculizumab: a case report","volume":"96","author":"Abe","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.cmi.2018.02.002_bib219","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMc1100859","article-title":"Eculizumab in severe Shiga-toxin-associated HUS","volume":"364","author":"Lapeyraque","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.02.002_bib220","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/ndt\/gfw453","article-title":"Eculizumab in secondary atypical haemolytic uraemic syndrome","volume":"32","author":"Cavero","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.cmi.2018.02.002_bib221","first-page":"347","article-title":"Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab","volume":"30","author":"Asif","year":"2017","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.cmi.2018.02.002_bib222","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/1076029615598221","article-title":"Hematopoietic stem cell transplant-associated thrombotic microangiopathy","volume":"22","author":"Elsallabi","year":"2016","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.cmi.2018.02.002_bib223","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1016\/j.bbmt.2017.08.019","article-title":"Thrombotic microangiopathy after allogeneic stem cell transplantation \u2013 a comparison of eculizumab therapy and conventional therapy","volume":"23","author":"Bohl","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.cmi.2018.02.002_bib224","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/tri.12551","article-title":"A\u00a0case of thrombotic micro-angiopathy after heart transplantation successfully treated with eculizumab","volume":"28","author":"Morales","year":"2015","journal-title":"Transpl Int"},{"key":"10.1016\/j.cmi.2018.02.002_bib225","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/bmt.2016.87","article-title":"Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy","volume":"51","author":"Vasu","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cmi.2018.02.002_bib226","doi-asserted-by":"crossref","first-page":"748","DOI":"10.2215\/CJN.12901211","article-title":"Eculizumab for dense deposit disease and C3 glomerulonephritis","volume":"7","author":"Bomback","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.cmi.2018.02.002_bib227","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.2215\/CJN.06230614","article-title":"Molecules great and small: the complement system","volume":"10","author":"Mathern","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.cmi.2018.02.002_bib228","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/tri.12706","article-title":"Complement inhibition as potential new therapy for antibody-mediated rejection","volume":"29","author":"Eskandary","year":"2016","journal-title":"Transpl Int"},{"key":"10.1016\/j.cmi.2018.02.002_bib229","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1097\/TP.0000000000000184","article-title":"Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts","volume":"98","author":"Burbach","year":"2014","journal-title":"Transplantation"},{"key":"10.1016\/j.cmi.2018.02.002_bib230","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/tri.12396","article-title":"Antibody-mediated rejection despite inhibition of terminal complement","volume":"27","author":"Bentall","year":"2014","journal-title":"Transpl Int"},{"key":"10.1016\/j.cmi.2018.02.002_bib231","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1111\/j.1600-6143.2011.03757.x","article-title":"Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients","volume":"11","author":"Stegall","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cmi.2018.02.002_bib232","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/ajt.13168","article-title":"Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1 year","volume":"15","author":"Cornell","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cmi.2018.02.002_bib233","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ophtha.2013.09.044","article-title":"Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study","volume":"121","author":"Yehoshua","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.cmi.2018.02.002_bib234","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2015-09-669770","article-title":"Eculizumab salvage therapy for delayed hemolysis transfusion reaction in sickle cell disease patients","volume":"127","author":"Dumas","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2018.02.002_bib235","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/ana.24770","article-title":"Therapy with eculizumab for patients with CD59\u00a0p.Cys89Tyr mutation","volume":"80","author":"Mevorach","year":"2016","journal-title":"Ann Neurol"},{"key":"10.1016\/j.cmi.2018.02.002_bib236","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1517\/14712598.2012.668517","article-title":"Eculizumab for treatment of asthma","volume":"12","author":"Smith","year":"2012","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.cmi.2018.02.002_bib237","first-page":"1421","article-title":"[Novel therapeutic interventions in Guillain\u2013Barr\u00e9 syndrome: review and future perspective]","volume":"67","author":"Misawa","year":"2015","journal-title":"Brain Nerve"},{"key":"10.1016\/j.cmi.2018.02.002_bib238","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","article-title":"Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study","volume":"12","author":"Pittock","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.cmi.2018.02.002_bib239","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/mus.23839","article-title":"A\u00a0randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis","volume":"48","author":"Howard","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.cmi.2018.02.002_bib240","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S0022-3476(96)70436-5","article-title":"Invasive Haemophilus influenzae type b infection in a child with familial deficiency of the \u03b2 subunit of the eighth component of complement","volume":"128","author":"Pallares","year":"1996","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.cmi.2018.02.002_bib241","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1128\/jcm.27.5.1045-1049.1989","article-title":"Comparison of isolates of Neisseria gonorrhoeae causing meningitis and report of gonococcal meningitis in a patient with C8 deficiency","volume":"27","author":"Del Rio","year":"1989","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.cmi.2018.02.002_bib242","first-page":"1","article-title":"Prevention and control of meningococcal disease: recommendations of the advisory Committee on immunization practices (ACIP)","volume":"62","author":"Cohn","year":"2013","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.cmi.2018.02.002_bib243","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1007\/s00467-011-1929-3","article-title":"Insufficient protection by Neisseria meningitidis vaccination alone during eculizumab therapy","volume":"26","author":"Bouts","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.cmi.2018.02.002_bib244","first-page":"184","article-title":"Fatal Neisseria meningitidis serogroup X sepsis in immunocompromised patients in Spain. Virulence of clinical isolates","volume":"64","author":"Vicente","year":"2012","journal-title":"J\u00a0Infect"},{"key":"10.1016\/j.cmi.2018.02.002_bib245","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/ajt.12032","article-title":"Meningococcal sepsis complicating eculizumab treatment despite prior vaccination","volume":"13","author":"Struijk","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cmi.2018.02.002_bib246","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.eimc.2012.06.011","article-title":"[Meningococcemia during eculizumab treatment]","volume":"31","author":"Rey-Mugica Mde","year":"2013","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"65","key":"10.1016\/j.cmi.2018.02.002_bib247","first-page":"696","article-title":"Notes from the field: meningococcal disease in an international traveler on eculizumab therapy \u2013 United States","volume":"2016","author":"Applegate","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.cmi.2018.02.002_bib248","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.eimc.2016.02.015","article-title":"Meningococcemia in vaccinated patient under treatment with eculizumab","volume":"35","author":"Hernando Real","year":"2017","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.cmi.2018.02.002_bib249","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00277-017-2951-8","article-title":"Waterhouse-Friderichsen syndrome due to Neisseria meningitidis infection in a young adult with thrombotic microangiopathy and eculizumab treatment: case report and review of management","volume":"96","author":"Friedl","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.cmi.2018.02.002_bib250","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic\u2013uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"64","key":"10.1016\/j.cmi.2018.02.002_bib251","first-page":"608","article-title":"Use of serogroup B meningococcal vaccines in persons aged \u226510 years at increased risk for serogroup B meningococcal disease: recommendations of the Advisory Committee on Immunization Practices","volume":"2015","author":"Folaranmi","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.cmi.2018.02.002_bib252","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1016\/S0264-410X(03)00440-7","article-title":"Long term effects of vaccination of patients deficient in a late complement component with a tetravalent meningococcal polysaccharide vaccine","volume":"21","author":"Platonov","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2018.02.002_bib253","doi-asserted-by":"crossref","first-page":"4946","DOI":"10.1128\/IAI.70.9.4946-4954.2002","article-title":"Effect of vaccination with Carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection","volume":"70","author":"Burrage","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.cmi.2018.02.002_bib254","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1128\/CDLI.7.5.764-768.2000","article-title":"Relationship between serum bactericidal activity and serogroup-specific immunoglobulin G concentration for adults, toddlers, and infants immunized with Neisseria meningitidis serogroup C vaccines","volume":"7","author":"Sikkema","year":"2000","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.cmi.2018.02.002_bib255","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.idc.2015.08.002","article-title":"The changing epidemiology of meningococcal disease","volume":"29","author":"Cohn","year":"2015","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.cmi.2018.02.002_bib256","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.4161\/hv.25505","article-title":"Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine","volume":"9","author":"Santolaya","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.cmi.2018.02.002_bib257","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/INF.0b013e3182503849","article-title":"Gonococcal septic shock associated with eculizumab treatment","volume":"31","author":"Gleesing","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2018.02.002_bib258","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1097\/OLQ.0000000000000202","article-title":"Disseminated gonococcal infection and eculizumab\u2014a \u201chigh risk\u201d connection?","volume":"41","author":"Hublikar","year":"2014","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.cmi.2018.02.002_bib259","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1111\/j.1600-6143.2012.04051.x","article-title":"Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH\/CFHR1 hybrid protein","volume":"12","author":"Krid","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cmi.2018.02.002_bib260","first-page":"908087","article-title":"Necrotizing fasciitis in paroxysmal nocturnal hemoglobinuria","volume":"2015","author":"Patir","year":"2015","journal-title":"Case Rep Hematol"},{"key":"10.1016\/j.cmi.2018.02.002_bib261","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/tid.12517","article-title":"Recurrent infection with Pseudomonas aeruginosa during eculizumab therapy in an allogeneic hematopoietic stem cell transplant recipient","volume":"18","author":"Webb","year":"2016","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.cmi.2018.02.002_bib262","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.virol.2010.12.045","article-title":"Complement and viral pathogenesis","volume":"411","author":"Stoermer","year":"2011","journal-title":"Virology"},{"key":"10.1016\/j.cmi.2018.02.002_bib263","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s12105-013-0516-2","article-title":"Acute necrotizing herpetic tonsillitis: a report of two cases","volume":"9","author":"Borhan","year":"2015","journal-title":"Head Neck Pathol"},{"key":"10.1016\/j.cmi.2018.02.002_bib264","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1212\/WNL.0000000000002312","article-title":"Eculizumab-related progressive multifocal leukoencephalopathy","volume":"86","author":"Gomez-Cibeira","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.cmi.2018.02.002_bib265","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1439-0507.2008.01597.x","article-title":"Complement and fungal pathogens: an update","volume":"51","author":"Speth","year":"2008","journal-title":"Mycoses"},{"key":"10.1016\/j.cmi.2018.02.002_bib266","doi-asserted-by":"crossref","first-page":"631","DOI":"10.3109\/0886022X.2014.882712","article-title":"Aspergillus niger peritonitis in a peritoneal dialysis patient treated with eculizumab","volume":"36","author":"Vellanki","year":"2014","journal-title":"Ren Fail"},{"key":"10.1016\/j.cmi.2018.02.002_bib267","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.clim.2015.05.018","article-title":"Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome","volume":"160","author":"Volokhina","year":"2015","journal-title":"Clin Immunol"},{"key":"10.1016\/j.cmi.2018.02.002_bib268","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.bbmt.2013.12.565","article-title":"Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"20","author":"Jodele","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.cmi.2018.02.002_bib269","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.bbmt.2015.10.002","article-title":"Variable eculizumab clearance requires pharmacodynamic monitoring to optimize therapy for thrombotic microangiopathy after hematopoietic stem cell transplantation","volume":"22","author":"Jodele","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.cmi.2018.02.002_bib270","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1182\/blood-2014-03-560540","article-title":"Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab","volume":"125","author":"Peffault de Latour","year":"2015","journal-title":"Blood"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X18301502?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X18301502?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T19:22:23Z","timestamp":1693509743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X18301502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":270,"alternative-id":["S1198743X18301502"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2018.02.002","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors)","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2018.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}